Microglial Therapeutic Potential in Alzheimer's Disease: From Phenotypic Diversity to Targeted Interventions.
- 1Department of Biology, Faculty of Biology, Alexandru Ioan Cuza University of Iasi, 700506 Iasi, Romania.
- 2Advanced Research and Development Center for Experimental Medicine "Prof. Ostin C. Mungiu", Grigore T. Popa University of Medicine and Pharmacy Iasi, 700454 Iasi, Romania.
- 3Department of Pharmacology, Clinical Pharmacology and Algesiology, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by β-amyloid (Aβ) deposition, tau pathology and cognitive decline. Increasing evidence from genetic, transcriptomic, experimental and clinical studies has identified microglia as key regulators of AD pathogenesis. Under physiological conditions, microglia maintain central nervous system homeostasis through immune surveillance, phagocytosis and neurotrophic support. However, persistent exposure to pathological stimuli promotes a shift toward dysfunctional inflammatory states that contribute to neuroinflammation, synaptic impairment, tau propagation and neurodegeneration. Recent advances have revealed substantial microglial heterogeneity, highlighting the existence of dynamic and disease stage-dependent activation states rather than fixed phenotypes. In early disease stages, microglia can promote Aβ clearance and tissue repair, whereas chronic activation may exacerbate pathological processes. These findings have driven the development of microglia-targeted therapeutic strategies aimed at enhancing protective functions while limiting maladaptive inflammatory responses. This review summarizes current knowledge regarding microglial involvement in AD and discusses emerging therapeutic approaches, ranging from immunomodulation and metabolic reprogramming to gene-based and nanotechnology-driven interventions, with a focus on their translational potential.
Related
- Dexmedetomidine as a potential neuroprotective agent against Alzheimer’s disease: molecular mechanisms and therapeutic perspectives
- Neuroinflammation in Alzheimer’s disease: pathogenic signaling, biomarkers, and emerging therapeutic interventions
- Shared mechanisms and therapeutic horizons: exploring the potential interplay between benign prostatic hyperplasia/lower urinary tract symptoms and Alzheimer’s disease
- Targeting Specific Sirtuin Modulation: Emerging Therapeutic Strategies for Healthy Cognitive Ageing and Potential Implications for Alzheimer’s Disease
- Multi-omics analysis of potential therapeutic targets for Alzheimer’s disease and associated differences in immune cell infiltration
BibTeX
@article{gogu2026microglial,
title = {{Microglial Therapeutic Potential in Alzheimer's Disease: From Phenotypic Diversity to Targeted Interventions.}},
author = {Maria-Raluca Gogu and Ivona Mazarianu and Gabriela-Dumitrita Stanciu and Bogdan-Ionel Tamba and Mitica Ciorpac and Dragos-Lucian Gorgan},
journal = {Pharmaceuticals (Basel, Switzerland)},
year = {2026},
month = oct,
doi = {10.3390/ph19101603},
url = {https://europepmc.org/article/MED/42943300},
note = {CC BY},
}
RIS
TY - JOUR
TI - Microglial Therapeutic Potential in Alzheimer's Disease: From Phenotypic Diversity to Targeted Interventions.
AU - Maria-Raluca Gogu
AU - Ivona Mazarianu
AU - Gabriela-Dumitrita Stanciu
AU - Bogdan-Ionel Tamba
AU - Mitica Ciorpac
AU - Dragos-Lucian Gorgan
PY - 2026
DA - 2026/10/09
JO - Pharmaceuticals (Basel, Switzerland)
DO - 10.3390/ph19101603
UR - https://europepmc.org/article/MED/42943300
AB - Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by β-amyloid (Aβ) deposition, tau pathology and cognitive decline. Increasing evidence from genetic, transcriptomic, experimental and clinical studies has identified microglia as key regulators of AD pathogenesis. Under physiological conditions, microglia maintain central nervous system homeostasis through immune surveillance, phagocytosis and neurotrophic support. However, persistent exposure to pathological stimuli promotes a shift toward dysfunctional inflammatory states that contribute to neuroinflammation, synaptic impairment, tau propagation and neurodegeneration. Recent advances have revealed substantial microglial heterogeneity, highlighting the existence of dynamic and disease stage-dependent activation states rather than fixed phenotypes. In early disease stages, microglia can promote Aβ clearance and tissue repair, whereas chronic activation may exacerbate pathological processes. These findings have driven the development of microglia-targeted therapeutic strategies aimed at enhancing protective functions while limiting maladaptive inflammatory responses. This review summarizes current knowledge regarding microglial involvement in AD and discusses emerging therapeutic approaches, ranging from immunomodulation and metabolic reprogramming to gene-based and nanotechnology-driven interventions, with a focus on their translational potential.
SN - 1424-8247
ER -